| Description | Saroglitazar (Lipaglyn) is an agonist of PPAR with EC50 values of 0.65 pM and 3 nM for PPARα and PPARγ. |
| In vivo | 在db/db小鼠中，Saroglitazar (口服剂量为0.01-3 mg/kg) 以剂量依赖性方式降低血清甘油三酯、游离脂肪酸和葡萄糖（ED50分别为0.05, 0.19, 以及0.19 mg/kg）。Saroglitazar (1 mg/kg) 显著降低血清胰岛素和AUC-葡萄糖(削减91%)[3]。 |
| Target activity | PPARγ:3 nM （EC50， HepG2 cell）, PPARα:0.65 pM （EC50， HepG2 cell） |
| Synonyms | Lipaglyn |
| molecular weight | 439.57 |
| Molecular formula | C25H29NO4S |
| CAS | 495399-09-2 |
| Storage | keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 22.5mg/mL (51.2mM) |
| References | 1. Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136. |